HK1206760A1 - 受體激動劑結合物 - Google Patents
受體激動劑結合物Info
- Publication number
- HK1206760A1 HK1206760A1 HK15107435.1A HK15107435A HK1206760A1 HK 1206760 A1 HK1206760 A1 HK 1206760A1 HK 15107435 A HK15107435 A HK 15107435A HK 1206760 A1 HK1206760 A1 HK 1206760A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptor agonist
- agonist combinations
- combinations
- receptor
- agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261616929P | 2012-03-28 | 2012-03-28 | |
PCT/US2013/034163 WO2013148877A1 (en) | 2012-03-28 | 2013-03-27 | Dr5 receptor agonist combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206760A1 true HK1206760A1 (zh) | 2016-01-15 |
Family
ID=48087754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15107435.1A HK1206760A1 (zh) | 2012-03-28 | 2015-08-03 | 受體激動劑結合物 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20150056204A1 (zh) |
EP (1) | EP2831116A1 (zh) |
JP (1) | JP6219923B2 (zh) |
AU (1) | AU2013239682B2 (zh) |
CA (1) | CA2867631C (zh) |
HK (1) | HK1206760A1 (zh) |
MX (1) | MX350202B (zh) |
WO (1) | WO2013148877A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11299528B2 (en) | 2014-03-11 | 2022-04-12 | D&D Pharmatech Inc. | Long acting TRAIL receptor agonists for treatment of autoimmune diseases |
EP3048116A1 (en) * | 2015-01-23 | 2016-07-27 | International-Drug-Development-Biotech | Anti-dr5 antibodies with enhanced apoptosis potency |
JP6602875B2 (ja) | 2015-01-26 | 2019-11-06 | マクロジェニクス,インコーポレーテッド | Dr5結合ドメインを含む多価分子 |
WO2017028279A1 (en) * | 2015-08-19 | 2017-02-23 | Beijing Cotimes Biotech Company Limited | Trail receptor-binding agents and uses of same |
CA3008392C (en) | 2015-12-17 | 2021-11-09 | The Johns Hopkins University | Ameliorating systemic sclerosis with death receptor agonists |
CA3020339C (en) | 2016-04-07 | 2022-05-03 | The Johns Hopkins University | Compositions and methods for treating pancreatitis and pain with death receptor agonists |
KR101926834B1 (ko) * | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
EP3672634A1 (en) * | 2017-08-24 | 2020-07-01 | Invenra, Inc. | Multivalent receptor-clustering agonist antibody constructs |
EP4277706A1 (en) * | 2021-01-15 | 2023-11-22 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
ATE156158T1 (de) | 1992-04-14 | 1997-08-15 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
US6998116B1 (en) | 1996-01-09 | 2006-02-14 | Genentech, Inc. | Apo-2 ligand |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ATE362982T1 (de) | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
US7528239B1 (en) | 1997-02-13 | 2009-05-05 | Immunex Corporation | Receptor that binds trail |
US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
US6100082A (en) | 1997-09-23 | 2000-08-08 | Hassanein; Waleed H. | Perfusion apparatus and method including chemical compositions for maintaining an organ |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP2002543151A (ja) * | 1999-05-04 | 2002-12-17 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 死ドメイン含有レセプター5 |
US7279160B2 (en) * | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
JP4574350B2 (ja) | 2002-06-24 | 2010-11-04 | ジェネンテック, インコーポレイテッド | Apo−2リガンド/trail変異体とその使用法 |
GB0328261D0 (en) | 2003-12-05 | 2004-01-07 | Univ Groningen | Improved cytokine design |
US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
EP2292248A3 (en) | 2005-03-03 | 2011-06-29 | CovX Technologies Ireland Limited | Anti-angiogenic compounds |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
NZ576751A (en) | 2006-11-10 | 2011-10-28 | Covx Technologies Ireland Ltd | Anti-angiogenic compounds |
GB0704651D0 (en) * | 2007-03-09 | 2007-04-18 | Ucl Business Plc | Composition |
US9120855B2 (en) * | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
CA2799177A1 (en) * | 2010-05-14 | 2011-11-17 | Amgen Inc. | Enhanced death receptor agonists |
-
2013
- 2013-03-27 CA CA2867631A patent/CA2867631C/en not_active Expired - Fee Related
- 2013-03-27 MX MX2014011540A patent/MX350202B/es active IP Right Grant
- 2013-03-27 JP JP2015503545A patent/JP6219923B2/ja not_active Expired - Fee Related
- 2013-03-27 WO PCT/US2013/034163 patent/WO2013148877A1/en active Application Filing
- 2013-03-27 US US14/388,762 patent/US20150056204A1/en not_active Abandoned
- 2013-03-27 AU AU2013239682A patent/AU2013239682B2/en not_active Ceased
- 2013-03-27 EP EP13715858.0A patent/EP2831116A1/en not_active Withdrawn
-
2015
- 2015-08-03 HK HK15107435.1A patent/HK1206760A1/zh unknown
-
2018
- 2018-10-31 US US16/176,343 patent/US20190284290A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX350202B (es) | 2017-08-30 |
CA2867631C (en) | 2019-06-11 |
US20190284290A1 (en) | 2019-09-19 |
US20150056204A1 (en) | 2015-02-26 |
WO2013148877A1 (en) | 2013-10-03 |
EP2831116A1 (en) | 2015-02-04 |
AU2013239682B2 (en) | 2016-03-31 |
CA2867631A1 (en) | 2013-10-03 |
JP6219923B2 (ja) | 2017-10-25 |
AU2013239682A1 (en) | 2014-09-18 |
MX2014011540A (es) | 2015-03-06 |
JP2015512412A (ja) | 2015-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211039A1 (zh) | 工程化 細胞受體 | |
HK1208232A1 (zh) | 雙激動劑化合物及方法 | |
HK1203191A1 (zh) | 受體拮抗劑 | |
GB201213700D0 (en) | Receptor antagnists II | |
HK1204513A1 (zh) | 質量驅動型流 | |
PT2765990T (pt) | Dispersão sólida | |
HK1206760A1 (zh) | 受體激動劑結合物 | |
HK1205706A1 (zh) | 受體激動劑 | |
HK1207985A1 (zh) | 促生長素抑制素受體激動劑製劑 | |
HK1211025A1 (zh) | 吲哚啉類 | |
GB201223053D0 (en) | Receptor | |
EP2872138A4 (en) | NEUROPROTECTIVE AGONISTS OF CB2 RECEPTORS | |
HK1218647A1 (zh) | 血管加壓素- 受體激動劑 | |
GB2508723B (en) | Seat | |
GB201312010D0 (en) | Receptor Agonists | |
GB201113354D0 (en) | Leptin receptor structure | |
GB201216854D0 (en) | Agonist | |
GB201213699D0 (en) | Receptor antagonists II | |
GB201213698D0 (en) | Receptor antagonists II | |
PL2800497T3 (pl) | Unoszony oraz rozkładany mebel do siedzenia | |
AU346180S (en) | Spout | |
GB201214302D0 (en) | Seats |